Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 21,035 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Rheumatoid Arthritis
Interventions: PF-04171327 10 mg, Prednisone Placebo, PF-04171327 25 mg, Prednisone 5 mg, Placebo for PF-04171327, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Anniston, Alabama • Daytona Beach, Florida • Miami, Florida + 5 more

Conditions: Obesity, Overweight, Type 1 Diabetes Mellitus
Interventions: No intervention; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 7 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: Observational Non-Interventional Registry; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2100
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, Leukemia
Interventions: Ibrutinib, Fludarabine, Cyclophosphamide, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: CARE+; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Myeloma
Interventions: Lenalidomide, Bortezomib, Siltuximab, Dexamethasone, Questionnaires; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lupus Nephritis
Interventions: Voclosporin; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Glendale, Arizona • Atlanta, Georgia • Lawrenceville, Georgia + 3 more

Conditions: Rheumatoid Arthritis
Interventions: ABT-494, Placebo, Tofacitinib; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more

Conditions: Exercise-induced Inflammation, Exercise-induced Oxidative Stress, Exercise-induced Immune Dysfunction
Interventions: Nutrasorb, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
Interventions: (Anti-KIR); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: Amifostine, DHAP; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Interventions: LLS Program; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois • San Antonio, Texas

Conditions: HIV Infections
Interventions: Medication Reminder System/Adherence Tracker; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Interventions: Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Peripheral Blood Stem Cell Transplantation; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Colon Cancer
Interventions: AMR101 (VASCEPA, icosapent ethyl); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV/AIDS, HIV Infections, Substance Use, Substance Abuse, Substance Use Disorders, Sexually Transmitted Diseases
Interventions: Link2CARE; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Lymphoma
Interventions: recombinant interferon alfa, bexarotene; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 5
States / cities: Miami, Florida • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym023; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: All Conditions, All
Interventions: Not listed
Lead sponsor: Head Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Cambridge, Massachusetts

Conditions: Chronic Lymphocytic Leukemia
Interventions: Bendamustine, Obinutuzumab, Rituximab, Venetoclax; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: DiaPep277, Placebo; Drug
Lead sponsor: Andromeda Biotech Ltd.; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 26
States / cities: Los Gatos, California • Modesto, California • San Diego, California + 23 more

Search by objective public record fields.

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children

CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Computer Assisted Rx Education for HIV-Positives: CARE+

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Polyphenols, Exercise, and Metabolomics

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2)

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Innate Immunity in Allergic Asthma

Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults